|
|
|
|
| LEADER |
03996nmm a2200313 u 4500 |
| 001 |
EB000366162 |
| 003 |
EBX01000000000000000219214 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
130626 ||| eng |
| 020 |
|
|
|a 9781603275477
|
| 100 |
1 |
|
|a Sioud, Mouldy
|e [editor]
|
| 245 |
0 |
0 |
|a siRNA and miRNA Gene Silencing
|h Elektronische Ressource
|b From Bench to Bedside
|c edited by Mouldy Sioud
|
| 250 |
|
|
|a 1st ed. 2009
|
| 260 |
|
|
|a Totowa, NJ
|b Humana
|c 2009, 2009
|
| 300 |
|
|
|a XIV, 472 p
|b online resource
|
| 505 |
0 |
|
|a Methods for Selecting Effective siRNA Sequences by using Statistical and Clustering Techniques -- Deciphering the Code of Innate Immunity Recognition of siRNAs -- Targeted Delivery of Antisense Oligonucleotides and siRNAs into Mammalian Cells -- Local and Systemic Delivery of siRNAs for Oligonucleotides Therapy -- Imaging of siRNA Delivery and Silencing -- Recent Advances in Magnetofection and Its Potential to Deliver siRNAs In Vitro -- In Vitro and In Vivo Gene Silencing by TransKingdom RNAi (tkRNAi) -- Bacterial Delivery of siRNAs: A New Approach to Solid Tumor Therapy -- The Therapeutic Potential of LNA-modified siRNAs: Reduction of Off-target Effects by Chemical Modification of the siRNA Sequence -- pSM155 and pSM30 Vectors for miRNA and shRNA Expression -- Targeting Oncogenes with siRNAs -- Targeting Stromal-cancer Cell Interactions with siRNAs -- Therapeutic Potential of siRNA-mediated Targeting of Urokinase Plasminogen Activator, Its Receptor, and Matrix Metalloproteinases -- Silencing of HIF-1#x03B1; by RNA Interference in Human Glioma Cells In Vitro and In Vivo -- RNA Interference-Mediated Validation of Genes Involved in Telomere Maintenance and Evasion of Apoptosis as Cancer Therapeutic Targets -- Treating Respiratory Viral Diseases with Chemically Modified, Second Generation Intranasal siRNAs -- Progress in the Therapeutic Applications of siRNAs Against HIV-1 -- Protein Components of the microRNA Pathway and Human Diseases -- Intron-Mediated RNA Interference and microRNA Biogenesis -- Emergence of a Complex Relationship between HIV-1 and the microRNA Pathway -- Synthetic microRNA Targeting Glioma-associated Antigen-1 Protein -- Therapeutic Targeting of Gene Expression by siRNAs Directed Against BCR-ABL Transcripts in a Patient with Imatinib-Resistant Chronic Myeloid Leukemia
|
| 653 |
|
|
|a Medical Genetics
|
| 653 |
|
|
|a Molecular Genetics
|
| 653 |
|
|
|a Molecular genetics
|
| 653 |
|
|
|a Medical genetics
|
| 653 |
|
|
|a Biochemistry
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Methods in Molecular Biology
|
| 028 |
5 |
0 |
|a 10.1007/978-1-60327-547-7
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-60327-547-7?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 572
|
| 520 |
|
|
|a RNA interference has become a key method in the suppression of gene expression and the development of therapeutic agents, yet there is still the problem of delivery, stability, and the danger of off-target effects such as the silencing of unwanted genes and activation of innate immunity. In siRNA and miRNA Gene Silencing: From Bench to Bedside, expert researchers explore the most recent advances in siRNA design, expression, delivery, in vivo imaging, and methods to minimize siRNA's unwanted effects and promote successful use in patients. As part of the highly successful Methods in Molecular Biology™ series, the chapters focus on their respective subjects with easy-to-use, up-to-date information, including several step-by-step laboratory protocols on topics such as new delivery formulations and strategies with promising applications in vitro and in vivo, validated therapeutic target genes, and components of miRNA function, biogenesis, and interference with virus infection. Comprehensive and cutting-edge, siRNA and miRNA Gene Silencing: From Bench to Bedside offers an excellent collection of chapters to aid all those with an interest in RNAi, gene regulation, and new therapies
|